FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Drug Administration Schedule
Drug Approval
Female
Humans
Hyaluronoglucosaminidase
Injections, Subcutaneous
Middle Aged
Multicenter Studies as Topic
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Receptor, ErbB-2
Trastuzumab
Treatment Outcome
United States
United States Food and Drug Administration

authors with profiles

Abde Abukhdeir